A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer

Afatinib (also known as BIBW 2992) has recently been approved in several countries for the treatment of a distinct type of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer. This manuscript comprehensively reviews the preclinical data on afatinib, an irreversible inhibitor o...

Descripción completa

Detalles Bibliográficos
Autores principales: Modjtahedi, Helmout, Cho, Byoung Chul, Michel, Martin C., Solca, Flavio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4019832/
https://www.ncbi.nlm.nih.gov/pubmed/24643470
http://dx.doi.org/10.1007/s00210-014-0967-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4019832/
https://www.ncbi.nlm.nih.gov/pubmed/24643470
http://dx.doi.org/10.1007/s00210-014-0967-3

Ejemplares similares